Intelliseq funding news – Intelliseq Raises €4.5 Million in Latest Funding

Clinical genomics is changing how diseases are diagnosed and treated. Next-generation sequencing (NGS) provides deep insights into the human genome, helping doctors diagnose patients more quickly and tailor treatments based on their unique genetics.

Around 350 million people worldwide have rare genetic diseases, many of whom remain undiagnosed for years due to the limits of traditional lab methods. To unlock genomics' full potential, advanced technologies are needed to process large amounts of genetic data.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

Intelliseq was founded in 2014 by four scientists: Klaudia Szklarczyk-Smolana, Marcin Piechota, Michał Korostyński, and Sławomir Gołda. The company focuses on creating bioinformatics tools for automated DNA analysis and genetic diagnostics.

Their main platform, iFlow, helps laboratories create flexible and scalable workflows for genetic testing. It generates detailed reports for both doctors and patients, making genetic diagnostics faster more accurate, and more accessible. This innovation opens up new possibilities for personalized medicine.

According to Klaudia Szklarczyk-Smolana, PhD, CEO of Intelliseq, "genomics is still only scratching the surface of its potential. Currently, it is mainly used for diagnosing complex cases and profiling cancer, but its applications go far beyond that. Emerging genomic data banks and advanced analytical algorithms pave the way for precision healthcare, personalized treatments, and better drug compatibility for patients. This is exactly where bioinformatics solutions are headed.”

Intelliseq works with international research centers and labs through business and technology partnerships. They collaborate with organizations like the US-based Metrodora Institute and DNAnexus, which supports the UK Biobank, the world's largest genomic biobank.

With Metrodora Institute and its partner PrecisionLife, Intelliseq developed tools to assess risks for chronic fatigue syndrome and long COVID.

By connecting with the DNAnexus platform, Intelliseq can offer its genomic analysis tools to major healthcare systems, focusing on cancers and genetic diseases.

The investment was led by Vinci HiTech, with support from Unfold.vc and notable private investors, including Tadeusz Wesołowski, founder of Prosper S.A.

According to Luiza Nowacka, Investment Manager at Vinci S.A: "Intelliseq is already generating revenue in the US and has a solid foundation for further expansion. We see significant growth potential in this investment and a real opportunity for an attractive exit in the future. Beyond the high return potential, we see Intelliseq as a pioneer in Poland in leveraging genetics, bioinformatics, and artificial intelligence. We are committed to supporting groundbreaking technologies that can thrive in our country while making a real impact on medicine and improving patient outcomes.”

The funding will help Intelliseq expand internationally, especially in the US. It will also support the testing and use of its technology in diagnostic labs and the continued development of predictive algorithms, moving from traditional medicine to preventive healthcare.

About Intelliseq

Intelliseq offers advanced solutions for next-generation sequencing. Their team of bioinformaticians, geneticists, and molecular biologists work creatively and flexibly to solve DNA sequencing challenges.